Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.

Mayo Clinic proceedings·2026
Same author

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification.

Blood research·2026
Same author

Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Liver cancer·2026
Same author

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Impact of Transfusion Dependence on Clinical and Economic Burden in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Study.

Journal of blood medicine·2026
Same journal

Clinico-Pathologic Features of Adult Erdheim-Chester Disease in South Korea: A Multicenter Retrospective Study (KCSG LY22-15).

Cancer research and treatment·2026
Same journal

RETRACTION: Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy.

Cancer research and treatment·2026
Same journal

Up and Down of Cancer Research and Treatment (CRT)'s Journal Impact Factor at the Moment of CRT's 60th Anniversary.

Cancer research and treatment·2026
Same journal

Tumor-Intrinsic Hepatocyte Arm-Level Genomic States Shape Immunotherapy Response Heterogeneity in Hepatocellular Carcinoma.

Cancer research and treatment·2026
Same journal

Clinical Effectiveness and Cost-Effectiveness of Robot-Assisted Versus Conventional Esophagectomy.

Cancer research and treatment·2026
Same journal

A Multinational, Retrospective, Real-World Study: Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Beyond First-line in East Asia (HER2+ GASTA Study).

Cancer research and treatment·2026
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.8K

TTP-HUS associated with sunitinib.

Moon Ki Choi1, Jung Yong Hong, Jun Ho Jang

  • 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Cancer Research and Treatment
|August 19, 2009
PubMed
Summary
This summary is machine-generated.

Sunitinib, a cancer drug, can cause thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). Early recognition and treatment, including stopping sunitinib and plasmapheresis, led to a patient

Keywords:
Hemolytic uremic syndromePurpuraSunitinib malateThrombotic thrombocytopenic

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

20.9K

Related Experiment Videos

Last Updated: Jan 27, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

20.9K

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare, severe, and potentially fatal condition.
  • Drug-induced TTP-HUS is increasingly recognized, with chemotherapeutic agents frequently implicated.
  • Sunitinib is a targeted therapy used for metastatic renal cell carcinoma.

Purpose of the Study:

  • To report a case of TTP-HUS associated with sunitinib use in a patient with metastatic renal cell carcinoma.
  • To highlight the importance of recognizing and managing sunitinib-induced TTP-HUS.

Main Methods:

  • Case report of a patient presenting with TTP-HUS.
  • Clinical presentation included gross hematuria and generalized edema.
  • Laboratory findings revealed anemia, thrombocytopenia, elevated reticulocyte count, and schistocytes on peripheral blood smear.

Main Results:

  • The patient presented with symptoms consistent with TTP-HUS.
  • Discontinuation of sunitinib and initiation of plasmapheresis resulted in complete recovery.
  • Hematological parameters normalized post-treatment.

Conclusions:

  • Sunitinib can induce TTP-HUS in cancer patients.
  • Oncologists must be vigilant for TTP-HUS in patients treated with sunitinib.
  • Early diagnosis and prompt intervention, including drug cessation and plasmapheresis, are crucial for favorable outcomes.